Is Aldeyra Therapeutics (ALDX) Surpassing Other Healthcare Stocks in Performance This Year?

Medical Sector Standouts: How Aldeyra Therapeutics Is Leading the Pack

While the Medical sector boasts many promising stocks, savvy investors are always searching for those that consistently surpass their competitors. One such company to watch is Aldeyra Therapeutics (ALDX). Let's examine how ALDX has performed so far this year compared to its peers.

ALDX's Position in the Medical Sector

Aldeyra Therapeutics is among 925 companies classified within the Medical sector, which currently holds the #9 spot in the Zacks Sector Rank. This ranking system evaluates 16 different sectors by averaging the Zacks Rank of all stocks in each group, then orders them from strongest to weakest.

Why Zacks Rank Matters

The Zacks Rank is a trusted tool for identifying stocks with the potential to outperform the market over the next one to three months. It places special emphasis on upward revisions to earnings estimates, favoring companies with improving financial outlooks. At present, Aldeyra Therapeutics holds a Zacks Rank of #2 (Buy).

Recent Earnings Momentum

In the past quarter, analysts have raised their full-year earnings estimates for ALDX by 19.4%, reflecting growing optimism about the company's future performance.

Year-to-Date Performance

So far this year, ALDX has climbed approximately 6%. In contrast, the average return for Medical sector stocks is just 1.8%. This indicates that Aldeyra Therapeutics is outpacing the broader sector in 2024.

Other Notable Performers

Iovance Biotherapeutics (IOVA) is another Medical stock that has delivered impressive results, surging 40.3% year-to-date. Over the last three months, consensus earnings estimates for IOVA have increased by 16.4%, and the stock also carries a Zacks Rank #2 (Buy).

Industry Breakdown

• Aldeyra Therapeutics is part of the Medical - Drugs industry, which includes 140 companies and is currently ranked #138 by Zacks. This group has averaged a 4% gain this year, meaning ALDX is outperforming its industry peers.
• Iovance Biotherapeutics belongs to the Medical - Biomedical and Genetics industry, which comprises 447 stocks and holds the #87 spot. This industry has advanced 9% since the start of the year.

Looking Ahead

Investors interested in the Medical sector should keep a close eye on both Aldeyra Therapeutics and Iovance Biotherapeutics, as their strong momentum could continue in the months ahead.

Discover Zacks Top 10 Stocks for 2026

There's still time to get early access to Zacks' handpicked list of the top 10 stocks for 2026. Selected by Director of Research Sheraz Mian, this portfolio has consistently delivered remarkable results.

Since its launch in 2012 through November 2025, the Zacks Top 10 Stocks have soared +2,530.8%, far outpacing the S&P 500’s +570.3% return.

Sheraz Mian has carefully reviewed 4,400 companies covered by Zacks Rank to select the best 10 stocks to buy and hold for 2026. Be among the first to discover these high-potential picks.

More Investment Insights

Looking for additional recommendations? Download Zacks' 7 Best Stocks for the Next 30 Days for free.